Chromocell Names Frank Knuettel As Chief Executive Officer, Removing Interim Status Held Since July 2023
Chromocell Therapeutics Corp. ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its interim CEO Frank Knuettel, has been appointed as the Company's permanent CEO.
"I'm grateful to our board of directors and Chromocell's investors for their support over the past seven months and for the confidence they have shown in my ability to lead the Company," said Frank Knuettel, CEO of Chromocell. "I look forward to continuing to work with them and leading the effort to push forward our announced clinical and pre-clinical programs and developing additional programs based on our proprietary non-opioid pain therapy compound."
"Since being appointed Interim CEO, Frank has established himself as a goal-oriented and pragmatic leader," added Todd Davis, Chairman of the Board of Directors for the Company. "The Board is pleased to remove the "interim" title and believes Frank has the experience, knowledge, and strategic perspective to build our current programs, expand our portfolio of non-opioid pain treatment therapies, and seek suitable monetization of certain programs at the appropriate times."
Mr. Knuettel was previously appointed Interim CEO in July 2023, while currently serving as the Company's CFO, a role he will continue to fill for the near future.